Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5332624 | 0.93 | HRH3 (0.44) | HRH4HRH3ITKOPRM1OPRD1 | |
| SCHEMBL4965877 | 0.93 | HRH3 (0.44) | HRH4HRH3ITKOPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL4967345 | 0.80 | TRPM8 (0.37) | OPRM1OPRD1KCNH2OPRK1 | |
| Trifluoroacetic Acid SCHEMBL4964203 | 0.80 | OPRM1 (0.52) | OPRM1OPRD1RAB9AOPRK1 | |
| SCHEMBL3090217 | 0.74 | HRH3 (0.64) | HRH4HRH3ITKPARP1LTA4H | |
| Hydrochloric Acid SCHEMBL28918864 | 0.73 | HRH3 (0.62) | HRH4HRH3ITKPARP1LTA4H | |
| SCHEMBL4964378 | 0.72 | HDAC1 (0.52) | HRH3OPRM1OPRD1RAB9AOPRK1 | |
| SCHEMBL4966804 | 0.72 | HDAC1 (0.52) | HRH3OPRM1OPRD1RAB9AOPRK1 | |
| SCHEMBL19444786 | 0.72 | HRH3 (0.50) | HRH4HRH3ITKOPRM1OPRD1 | |
| SCHEMBL4965081 | 0.72 | OPRM1 (0.36) | OPRM1OPRD1DRD3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | claimed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | claimed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | claimed |
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | HRH4 378/4885HRH3 711/4885ITK 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.